MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Научная публикация · 2009

Lenalomide for the treatment of multiple myeloma in people who have received at least one prior therapy.

Перевод в очереди

Аннотация

Aims: This Technology Appraisal refers to the use of the drug Lenalomide for the treatment of multiple myeloma in people who have received at least one prior therapy. Recommendations: The guidance recommends lenalidomide in combination with dexamethasone as a treatment option for people with multiple myeloma who have received two or more prior therapies. The cost of the drug beyond 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer, Celgene. For those patients who have not received two or more prior therapies, but are currently receiving lenalidomide, the independent Appraisal Committee has recommended they have the option to continue treatment until they and their clinician consider it appropriate to stop. Intended audience: Healthcare professionals. Methodology and development: Section 4 'Consideration of the evidence' addresses the evidence of the clinical and cost effectiveness of lenalomide (Which could be used as an alternative to bortezomib) for the treatment of multiple myeloma in people who have received at least one prior therapy, and considers the findings of the evidence review group. (See also Appendix B of the guidance which outlines the sources of evidence considered by the committee). Implications for practice: The Secretary of State has directed that the NHS provides funding and resources for medicines and treatments that have been recommended by NICE technology appraisals normally within 3 months of the guidance being published. NB Following the BBC documentary The Price of Life broadcast on 17 June 2009, the Secretary of State's direction requiring NHS organisations to make funding available for NICE recommended treatments within 3 months of final guidance being published will begin on 24 June. Publication history information: Published 24 June 2009. NICE Technology Appraisal Guidance 171. Access: Available to the general public.

Для цитирования: Lenalomide for the treatment of multiple myeloma in people who have received at least one prior therapy.. 2009.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.